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OBJECTIVES The objectives of this review are to discuss the diversity of mechanisms that may explain the
association between heart rate (HR) variability and mortality, to appraise the clinical
applicability of traditional and new measures of HR variability and to propose future
directions in this field of research.
There is a large body of data demonstrating that abnormal HR variability measured over
a 24-h period provides information on the risk of subsequent death in subjects with and
without structural heart disease. However, the mechanisms responsible for this association are
not completely established. Therefore, no specific therapy is currently available to improve the
prognosis for patients with abnormal HR variability. Reduced HR variability has been most
commonly associated with a risk of arrhythmic death, but recent data suggest that abnormal
variability also predicts vascular causes of death, progression of coronary atherosclerosis and
death due to heart failure. A consensus is also lacking on the best HR variability measure for
clinical purposes. Time and frequency domain measures of HR variability have been most
commonly used, but recent studies show that new analysis methods based on nonlinear
dynamics may be more powerful in terms of risk stratification.
Before the measurement of HR variability can be applied to clinical practice and used to
direct therapy, more precise insight into the pathophysiological link between HR variability
and mortality are needed. Further studies should also address the issue of which of the HR
variability indexes, including the new nonlinear measures, is best for clinical purposes in
various patient populations. (J Am Coll Cardiol 1999;34:1878–83) © 1999 by the American
College of Cardiology
Analysis of heart rate (HR) variability from electrocardio-
graphic (ECG) recordings has become an important
method for assessing cardiovascular autonomic regulation.
Despite a large body of literature concerning HR variability
in cardiology and medical journals during the last decade
(.2,000 publications, Fig. 1), its measurement from the
Holter recordings has not yet become a routine clinical tool.
Since the observations by Kleiger et al. (1) that low standard
deviation in N-N intervals (SDNN) analyzed from a 24-h
ECG implied an increased risk of dying within three to four
years after an acute myocardial infarction (AMI), studies in
a number of different populations have confirmed these
relationships (2–15). Recently, a prospective multicenter
survey confirmed the previous results of retrospective studies
(16). Recent data also show that analyses of HR variability
by new methods based on nonlinear dynamics may perform
even better than the traditional measures in risk stratifica-
tion (17–19). Despite intensive research on various aspects
of HR variability, it is not yet fully established why patients
with abnormal HR variability die earlier than those with
normal variability. An understanding of mechanisms linking
abnormal HR variability to increased mortality might lead
to specific therapeutic strategies that may reduce the risk of
death for high risk patients.
The aims of this article are to provide a critical review of
our current knowledge of the potential reasons why abnor-
mal HR variability may increase mortality, to appraise the
clinical applicability of traditional and new methods of
measuring HR variability and to propose future directions
for HR variability research.
WHY DOES LOW HEART RATE
VARIABILITY PREDICT MORTALITY?
Most analyses of the HR variability data support the
observations that it is a predictor of sudden arrhythmic
death (19–24), based largely on epidemiological follow-up
studies. More recent work has shown that low HR variabil-
ity is also a predictor of nonarrhythmic cardiac events, such
as myocardial infarction (12), rapid progression of athero-
sclerosis (25) and death from heart failure (15).
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HR variability and arrhythmic death. A number of ob-
servational studies have shown that low HR variability is an
independent predictor of sudden cardiac death (3–
6,9,10,13). In fact, it has been suggested that HR variability
may be a better marker for increased risk of arrhythmic
events than any other noninvasive measure (3,9,10,26).
Despite the general acceptance that low HR variability is a
marker of increased risk of arrhythmic death, there are many
problems associated with the interpretation of the results
that are used to support this concept. The lack of a
definition of the exact mode of death is a major problem in
epidemiological follow-up studies. Sudden death has been
commonly attributed to arrhythmia, but recent data based
on stored ECGs of patients with implantable cardioverter-
defibrillators indicate that more than half of the deaths
defined as sudden (e.g., occurring within 1 h of the onset of
symptoms) are not arrhythmic (27,28). Even if stricter
criteria are used for defining arrhythmic death (29), all
definitions lack specificity with respect to defining the exact
mode of death. The definitions of arrhythmic events used in
epidemiological studies also tend to vary; some equate the
category of arrhythmic events with resuscitated ventricular
fibrillation; others use sustained ventricular tachycardia,
resuscitated ventricular fibrillation and sudden death as a
combined end point (10,26).
The incidence of both nonsudden and sudden death
among patients surviving an AMI has declined significantly
during the past two decades (1,30–32). As all deaths
occurring suddenly are not arrhythmic, the true incidence of
arrhythmic deaths is probably less than 2% per year in
consecutive survivors of AMI discharged from the hospital
with the best available therapy (32). In view of the low
number of deaths and the uncertainties about the mode of
death in epidemiological follow-up studies, even a large
multicenter survey (16) may not be able to give a definite
answer regarding the value of HR variability as a predictor
of arrhythmic death.
In case-control studies, HR variability has been compared
between survivors of documented arrhythmic events and
matched controls without a history of life-threatening
arrhythmia (33,34). These studies do not have the problem
of uncertainty about the mechanisms of arrhythmic events,
but there may be some problems in careful matching of the
patients with respect to all possible variables that could
influence their vulnerability to arrhythmic events and the
measures of HR variability. In general, case-control studies
have shown that HR variability is lower in arrhythmia
patients than in controls (33,34), but significant overlapping
in the measures of HR variability has been observed
between the two groups.
Analysis of HR behavior before the onset of life-
threatening arrhythmias could potentially provide insight
into the role of abnormal HR variability in the onset and
perpetuation of ventricular tachyarrhythmias. Data from
ambulatory recordings suggest that HR variability is altered
before the spontaneous onset of ventricular tachyarrhythmic
events, suggesting that abnormal variability may predispose
the patient to the onset of arrhythmias (35–38) or at least
mark the presence of a transient trigger. These observations
are based on relatively small numbers of selected patients,
however, and are, to some extent, controversial (35–38).
Studies in animals have convincingly shown that abnor-
mal autonomic regulation predisposes them to life-
threatening arrhythmias (39). Such experiments have used
acute coronary occlusion as a model for defining the role of
the autonomic nervous system in the genesis of arrhythmias
(39,40). The responses of this system to acute coronary
occlusion have been shown to predict ischemia-induced
ventricular fibrillation. Also, the baseline reflex autonomic
function, expressed as baroreflex sensitivity, has been shown
to predict ventricular fibrillation during subsequent coronary
occlusion in dogs without prior myocardial necrosis,
whereas baseline tonic autonomic function, expressed as HR
variability, does not (39). Acute coronary occlusion during
balloon angioplasty results in variable and unpredictable
changes in HR variability in humans (41,42). Recent data
have shown that the response of HR variability to acute
coronary occlusion is predictive of ischemia-induced com-
plex ventricular ectopic activity, but the baseline HR vari-
ability is not (43). Together, these observations support the
view that the responses of the autonomic nervous system to
acute hemodynamic changes or ischemia may be more
important in the genesis of life-threatening arrhythmias
than the baseline autonomic regulation, expressed as HR
variability.
These epidemiological, case-control and experimental
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Figure 1. The annual number of publications dealing with HRV
during the last decade based on search from the MEDLINE
system using the key word “heart rate variability.” HRV 5 heart
rate variability.
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data do not provide definite proof that the patients with
abnormal HR variability have an increased risk of experi-
encing a life-threatening arrhythmia event. To achieve that
goal, randomized intervention studies in the patients with
abnormal HR variability are needed to confirm the widely
accepted concept of an association between low HR vari-
ability and vulnerability to arrhythmic death. One pilot
study, the Nordic ICD study, involved the implantation of
a cardioverter-defibrillator in 33 patients with low HR
variability and impaired left ventricular function after an
AMI. During the median follow-up of 22 months, only one
patient experienced an appropriate shock from the device
(44). This suggests that low HR variability, measured as
SDNN, in combination with a reduced ejection fraction
measured in the convalescent phase of AMI, has a low
accuracy for predicting the occurrence of life-threatening
arrhythmic events.
HR variability and coronary events. Epidemiological
studies have provided evidence that abnormal HR variability
also predicts mortality in the general population. Data from
the Framingham Study show that low SDNN is a predictor
of death in the elderly (7), and data in younger subgroups
among the same cohort showed that low HR variability
predicts the occurrence of various adverse cardiac events
(12). In another unselected elderly population, abnormal
long-term HR variability predicted an increased risk of
dying during the 10-year follow-up (14). All these studies
including random samples of subjects from the general
population have shown that abnormal HR variability pre-
dicts various vascular events such as angina pectoris, myo-
cardial infarction and stroke mortality (7,12,14). These data
support the view that abnormal HR variability is not only a
marker of arrhythmic death, but also predicts a number of
other cardiac and vascular events.
It has been shown recently that reduced HR variability
and elevated 24-h HR predict the progression of human
coronary atherosclerosis as assessed in serial quantitative
coronary angiograms (25). Fast HR has been observed to
predispose to the rapid progression of atherosclerosis in
several animal models (45–47). The explanation of the
associations observed between HR, HR variability and the
progression of atherosclerosis may lie in the hemodynamic
factors. Progression of coronary lesions has been shown to
result from the effects of HR on blood flow dynamics at the
arterial wall (45,48). The effects of elevated HR and low HR
variability on the progression of coronary atherosclerosis
may well explain the finding that reduced SDNN predicts
late mortality better than early mortality in AMI patients
treated with modern thrombolytic therapy (8). Sudden
arrhythmic death is known to occur most commonly in the
early phase after the acute cardiovascular event (49), and the
progression of atherosclerosis and the occurrence of new
coronary events are more likely mechanisms of later death.
It should be noted in particular that rapid progression of
coronary artery disease is also common in other patient
populations with low HR variability and fast HR, e.g.,
diabetics and cardiac transplant recipients.
HR variability and progression of heart failure. Heart
failure is a common mechanism of death among patients
surviving a large AMI. Despite the improved therapeutic
options, progressive heart failure still remains an important
contributor to cardiovascular mortality. Although HR vari-
ability has been shown to be impaired in the patients with
heart failure (50), earlier studies have not pursued the notion
that low HR variability may be a prognostic marker of death
from progressive heart failure. Since reduced HR variability
and elevated HR reflect the degree of neurohumoral acti-
vation caused by impaired cardiac pump function, they may
influence left ventricular remodeling and the progression of
heart failure. A recent large study has shown that low
SDNN predicts death due to progressive heart failure but
not the sudden death of patients with congestive heart
failure (15).
Considered together, the data suggest that abnormal HR
variability is a general risk marker for all common modes of
cardiac death: arrhythmic, vascular and hemodynamic. Neu-
rohumoral activation and altered sympathovagal interaction
are the most common mechanisms of abnormal HR vari-
ability of patients with heart disease. It is not surprising that
abnormal HR variability is able to predict various causes of
death, as neurohumoral and sympathetic activation contrib-
ute to arrhythmogenesis, progression of heart failure and
atherogenesis (51,52).
METHODS OF MEASURING HEART RATE VARIABILITY
There are numerous indexes that describe quantitative and
qualitative aspects of the oscillations of the R-R interval
around its mean value (53). An ideal method for clinical
work would be a single HR variability index that could be
calculated reliably on the basis of a simple, widely available
analytical method. At the moment, there is no consensus
about the best available index of HR variability for clinical
use, despite the efforts of the Task Force of the North
American Society of Pacing and Electrophysiology and the
European Society of Cardiology to unify and standardize
the methodology (53). Noisy data, artifacts, trends and
ectopic beats are the major practical problems encountered
in HR variability measurements. Reviews of these problems
are described in detail elsewhere, and only some points are
discussed here (54,55).
Traditional methods for analyzing HR variability.
Twenty-four hour ambulatory recordings are most com-
monly used to assess the prognostic significance of HR
variability (1–12). Recordings made under uncontrolled
conditions over a 24-h period are always subject to noise,
unstationarities, artifacts and premature beats with variable
coupling intervals and compensatory pauses. Despite im-
provements in computer techniques for processing R-R
interval data, meticulous manual editing is needed to iden-
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tify and label the R-R intervals as “normal beats” or
“abnormal beats,” a technique that is prone to subjective
bias. Various automatic algorithms have been developed to
exclude artifacts and ectopic beats from the sinus intervals.
R-R intervals that differ by more than 20% to 30% from the
preceding ones are usually automatically excluded in time-
domain analysis and the gaps filled by various methods in
the spectral analysis of HR variability. All these methods are
arbitrary. It is obvious that the 20% to 30% rule will exclude
some genuine data, particularly in high-risk patients who
often show abrupt changes in sinus intervals (56). On the
other hand, ectopic beats with a long coupling interval may
remain unedited. The most reliable analysis of HR variabil-
ity can be obtained from subjects without ectopic beats, but
this is often not the case in the patients with heart disease.
Varying figures are used for the minimum number of
qualified sinus beats required for the data to be acceptable
for analysis, ranging from 99% to 70%. The most strict
criteria do not allow recordings with .10 premature beats/h
(57), but some investigators have included only patients
with .10 premature beats/h (6,37). It should be noted,
however, that 20% to 30% of all high-risk patients in
post-AMI populations are usually excluded from any anal-
ysis of HR variability due to frequent ectopy, artifacts or
episodes of atrial arrhythmias. None of the follow-up
studies has reported a mortality rate for these patients, but
it may well be even higher than for patients with low HR
variability.
The most commonly used prognostic HR variability
index has been the SDNN analyzed over a 24-h period
(1,2,7,8). The geometric triangular analysis methods devel-
oped by Malik et al. (58) perform as well as the traditional
time-domain analysis methods for risk stratification and do
not suffer from the bias of human editing, but they are not
widely available in commercial analysis systems. Spectral
analysis of HR variability allows assessment of frequency-
specific fluctuations in HR behavior and provides prognostic
information beyond the time-domain measures (6). The
spectral methods are invalidated for wide clinical applica-
tions by their numerous technical problems, e.g., the even
more prominent influence of ectopy and unstationarity on
the results than in statistical or geometrical methods.
Poincare` plot analysis of R-R intervals allows visual and
quantitative analysis of instantaneous and continuous R-R
interval variability and also provides more powerful prog-
nostic information on patients with heart failure and on
arrhythmic risk than the traditional time-domain methods
(11,36). Although all the statistical, geometrical and spectral
measures of HR variability differ in their manner of com-
putation and analysis, these methods are fundamentally
based on moment statistics and describe the magnitude of
HR variability. It is therefore not surprising that the
traditional nonspectral measures, including quantitative
Poincare` plot analysis and the spectral measures all have a
relatively close mutual correlation (59), and that there are
only minor differences in prognostic power between them.
The average 24-h HR also correlates relatively well with all
the traditional measures of HR variability (61), and one
study has shown that the prognostic information provided
by the average 24-h HR is almost as powerful as that
obtained from a measurement of time domain HR variabil-
ity (9).
New methods of analyzing HR variability based on
nonlinear dynamics. Analytic methods derived from non-
linear dynamics based on chaos theory and fractal mathe-
matics have opened new approaches for studying and
understanding the characteristics of HR behavior (60,61).
These methods differ from the traditional measures of
HR variability in that they are not designed to assess
the magnitude of variability. Rather, they estimate the
correlation properties and complexity of HR variability and
other features in HR dynamics that are not uncovered by
methods based on means and variance. It is notable that
only a weak correlation exists between these new nonlinear
measures and traditional measures (62,63). Methods of
analyzing the fractal-like correlation properties of HR
behavior have been most commonly used to detect abnor-
malities in R-R interval dynamics in various cardiovascular
disorders (13,14,18,62,63).
Several studies suggest that nonlinear dynamics may be
involved in the genesis of HR variability (60–63), but the
clinical applicability of the methods based on nonlinear
dynamics has not been tested in large-scale studies until
recently (13,14,17–19). Analysis of l/f characteristics, i.e.,
the inverse power-law slope, has provided prognostic infor-
mation beyond the traditional HR variability measures in
two populations (13,14). Data on the patients with de-
pressed left ventricular function show that fractal analysis of
HR variability yields more powerful prognostic information
than the traditional nonspectral and spectral measures
(18,19) (Fig. 2). Altered fractal properties of R-R intervals
have also been shown recently to precede the spontaneous
onset of ventricular fibrillation without evident abnormali-
ties in traditional indexes of HR variability (63). Of partic-
ular note is the fact that some fractal analysis techniques do
not require preprocessing or editing of premature beats
which may be of practical importance. Fractal analysis
methods seem at present to be promising means in risk
stratification, but more prospective studies in other popula-
tions performed by independent investigators will be needed
to establish their clinical utility.
FUTURE DIRECTIONS
There are a number of commercial analytical systems that
can reliably detect and measure R-R intervals from ambu-
latory recordings and calculate various indexes of HR
variability. Manufacturers use a variety of methods for
dealing with ectopic beats and artifacts and for analyzing
nonspectral and spectral HR variability indexes. The devel-
opment of these software systems has not been guided in
any way but has been left to free market forces (64).
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Similarly, no standardization has been established for the
various commercial systems. More research will still be
needed to compare the prognostic value and clinical utility
of the various traditional and new HR variability measures
before an ideal index can be introduced for clinical inter-
vention purposes and for development by commercial man-
ufacturers.
Before the measurement of HR variability can be con-
sidered to be of any clinical value, however, therapeutic
interventions are needed in the patients who present with
abnormal values. Ongoing research (65,66) should provide
important information on whether antiarrhythmic therapy
can improve the survival of patients with impaired left
ventricular function and low 24-h HR variability. Trials
aimed at preventing the progression of heart failure in such
patients by means of modern pharmacological agents should
also be of clinical importance, as will trials estimating the
effects of antiatherogenic therapy on progression of athero-
sclerosis of patients with fast HR and low HR variability.
Pharmacological or nonpharmacological interventions
should be sought for improving 24-h HR variability. It will
also be important to study whether an improvement in HR
variability can actually prevent mortality in order to avoid
the misconception of the 1980s that abolishing premature
ventricular beats with antiarrhythmic drugs could reduce
mortality.
Before the results of the abovementioned ongoing and
planned research efforts are available, the measurement of
HR variability by various methods remains a fascinating
research toy but not a routine clinical tool. If the intensive
research into various aspects of HR variability continues to
increase exponentially as it has done during the last decade,
it is possible that the measurement of a simple HR variabil-
ity index will become a routine clinical procedure compara-
ble with the measurement of blood pressure or plasma
cholesterol in the not-too-distant future.
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